WO1998042735A1 - Neue monomerbausteine zur markierung von peptidischen nukleinsäuren - Google Patents
Neue monomerbausteine zur markierung von peptidischen nukleinsäuren Download PDFInfo
- Publication number
- WO1998042735A1 WO1998042735A1 PCT/EP1998/001723 EP9801723W WO9842735A1 WO 1998042735 A1 WO1998042735 A1 WO 1998042735A1 EP 9801723 W EP9801723 W EP 9801723W WO 9842735 A1 WO9842735 A1 WO 9842735A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound according
- nucleobase
- nucleic acid
- radical
- Prior art date
Links
- IYDAAKYWTLQDLH-UHFFFAOYSA-N CCC(C)(CC)[NH+](C)[O-] Chemical compound CCC(C)(CC)[NH+](C)[O-] IYDAAKYWTLQDLH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to new monomer building blocks for labeling peptide nucleic acids and similarly constructed nucleic acid-binding oligomers with groups which are coupled to a nucleobase and / or to the peptide backbone of the peptide nucleic acid.
- the invention further relates to peptide nucleic acids which contain at least one labeled monomeric building block.
- marker groups e.g. B. Reporter molecules in nucleic acids are of great importance for many applications.
- the prerequisite here is the targeted installation of couplable groups, e.g. B. amino groups, in the nucleic acid.
- couplable groups e.g. B. amino groups
- specially modified monomeric nucleotide building blocks are produced which are compatible with the nucleic acid synthesis strategy subsequently used.
- B. Trifluoroacetyl- or Fmoc-protected aminoalkyloxy phosphoramidites are used for a 5 'end label (cf., for example, EP-A-224 578, Coull et al., Tetra-hedron Lett. 27 (1986), 3991 - 3994).
- phosphoramidites which contain a trifluoroacetyl or Fmoc-protected amino acid group and a DMTr ether, the base bodies being of a non-nucleotide nature (EP-A-0 313 219, Nelson et al., Nucleic Acids Res. 17 ( 1989, 7179-7186) or nucleotidic in nature (Ruth, DNA 4 (1985), 93, WO 84/03285).
- certain positions of the nucleobase or sugar come into play for the coupling of reporter molecules Question (see e.g. Ruth (1991) Oligodeoxynucleotides with reporter groups attached to the base, in: Oligonucleotides and Analogues: A Practical Approach
- nucleoside triphosphates modified on the nucleobase or on the ribose for the enzymatic construction of a nucleic acid are also known (EP-A-0063 879, EP-A-0286 898).
- the functional groups capable of coupling reporter molecules can be blocked by a suitable protective group, so that the coupling of the reporter group can only be carried out after the protective nucleus acid has been removed by so-called "postlabeling".
- a reporter molecule can also be coupled directly to the functional group, provided that it is stable under the conditions prevailing in nucleic acid synthesis and deprotection.
- An amino side group capable of coupling reporter molecules can also be introduced to inter-nucleotide phosphate groups by oxidizing the oligonucleotide phosphite triesters or H-phosphonate obtained with a mono-protected diamine to the corresponding phosphoramidate (WO 92/08728 and Agrawal et al., Nucleic Acids Res 18: 5419 (1990).
- PNA peptidic nucleic acids Due to the increased affinity and selectivity in the base pairing to a complementary nucleic acid counter-strand in comparison to conventional nucleic acids, peptidic nucleic acids (PNA) are becoming increasingly important when carrying out hybridization reactions (Egholm et al., J. Am. Chem. Soc. 114 (1992), 1895-1897, WO92 / 20 702 and WO 92/20 703).
- the sugar phosphate backbone of the nucleic acids is replaced by a peptide backbone, e.g. B. replaced a 2 -aminoethylglycine backbone.
- the nucleobases are on the central nitrogen atom z. B. coupled via a methylene carbonyl group.
- the synthesis of a PNA therefore differs significantly from DNA synthesis, since other protective groups and coupling chemistries are required.
- the introduction of functional groups for further derivatizations, e.g. B. for the introduction of reporter molecules, has so far been carried out directly at the N-terminus of the last PNA building block or after further coupling of one or more ⁇ -amino acids.
- a terminal introduction of functional groups was also possible by incorporating lysine residues at the C- and N-terminus.
- a first embodiment of the present invention relates to monomeric building blocks for the synthesis of nucleic acid-binding peptide oligomers which carry a labeling group or a group capable of coupling to a labeling group on the nucleobase.
- Such monomers are preferably represented by compounds of the formula (I):
- B is a natural or unnatural nucleobase which may have a protective group
- L is a labeling group, preferably selected from signaling groups, intercalators and pharmaceutically active groups, or a group capable of coupling to a labeling group, which optionally carries a protective group,
- A, C, D each independently represent chemical bonds or organic radicals
- E is a group selected from N, R 1 ⁇ or CH, where R 1 is an organic radical or hydrogen, Q is a group NR 2 Y, where R 2 is an organic radical or hydrogen, and Y is a protective group or a carrier ,
- I is a group selected from COX, CSX, SOX or S0 2 X, where X is OH, SH, OM, SM or a protective group and M is a cation, preferably a metal or ammonium cation and n is an integer from 1 to 3 , preferably 1.
- A, C and D are preferably can carry C L -C alkylene, alkenylene or alkynylene, which may optionally contain heteroatoms such as 0, N, P, or halogen and / or substituents.
- A is particularly preferably a - (CH 2 ) i-CO radical, where 1 is an integer from 0 to 5.
- A is most preferably a -CH 2 CO radical.
- C is particularly preferred - (CH 2 ) k -CHR 'radical, ..- where k is an integer from 0 to 5 and R' is hydrogen or the side chain is a naturally occurring amino acid.
- C is most preferably a - (CH 2 ) 2 radical.
- D is particularly preferably a (CH 2 ) m-CHR "radical, where m is an integer from 0 to 5 and R is hydrogen or the side chain of a naturally occurring amino acid.
- D is most preferably a -CH 2 radical.
- a and B or A and D can also be bridged to one another, ie form a common ring structure.
- the present invention relates to monomeric building blocks for the synthesis of nucleic acid-binding peptide oligomers which contain at least one signaling group on the peptide backbone.
- These monomer units are preferably compounds of the formula (II):
- L is a labeling group, preferably selected from signaling groups, intercalators and pharmaceutically active groups and n and m are 0 or 1 to 3, with the proviso that the sum of n + m is not 0. N and m are preferably 0 or 1.
- the group L is preferably a substituent of D.
- D is particularly preferably a group -CH (R'-L), where R 'is an organic radical as defined above.
- R ' is the rest of the side chain of a naturally occurring amino acid or the corresponding enantiomeric compound, e.g. B. Lysine.
- the asymmetric carbon atom of the group -C * H (R'-) preferably has the D configuration.
- the nucleobase of the compounds (I) and (II) is any natural or unnatural nucleobase, it being possible in principle to use all nucleobases which are capable of hybridizing with a complementary natural nucleobase on a DNA or RNA molecule.
- Nucleobase B is preferably selected from thymine, uracil, cytosine, adenine, guanine, hypoxanthine, purine, 7-deazapurine, 2,4-diaminopurine, 2,6-diaminopurine, 7-deazaguanine, pseudouracil, pseudocytosine, pseudoisocytosine, N 4 N 4 -ethanocytosine, N 6 , N 6 -ethano-2, 6-diamino-purine, 5- (C 3 -C 6 ) -alkynylcytosine, 5-fluorouracil or 2-hydroxy-5-methyl-4-triazolopyrimidine, where the nucleobase may have a protective group.
- the nucleobase B preferably carries one or more protective groups, in particular on exocyclic amino functions.
- a protecting group according to the present invention is a chemical group which prevents the functional group to which it is attached from participating in a chemical reaction which is not desired.
- the protective group can be removed from this functional group without destroying it.
- Suitable protective groups are base-labile protective groups such as. B. 9-fluorenylmethoxycarbonyl (Fmoc), 2,2- [bis (4-nitrophenyl)] ethoxycarbonyl (Bnpeoc), 2- (2,4-dinitrophenyl) ethoxycarbonyl (Dnpeoc), 2- (4-nitrophenyl ) -ethyloxycarbonyl, 1- (4, 4-dimethyl-2, 6-dioxocyclohexylidene) ethyl (Dde) and 2-methylsulfonylethyloxycarbonyl (Msc).
- Fmoc 9-fluorenylmethoxycarbonyl
- Bnpeoc 2,2- [bis (4-nitrophenyl)] ethoxycarbonyl
- Dnpeoc 2- (2,4-dinitrophenyl) ethoxycarbonyl
- Acid-labile protecting groups of the urethane type such as tert-butyloxycarbonyl (Boc), 4-methoxybenzyloxycarbonyl (Moz) or of the trityl type such as triphenylmethyl (Trt), (4-methoxyphenyl) diphenylmethyl (Mmt), (4 -Methylphenyl) diphenylmethyl (Mtt), di- (4-methoxyphenyl) phenylmethyl (Dmt) suitable.
- Boc, Trt, Mmt, Mtt and Dmt are particularly preferred.
- the group L is coupled to the nucleobase B.
- Preferred coupling positions are as follows: If the nucleobase is a pyrimidine base (C, T, U or an unnatural derivative thereof), the group L can preferably be bound to the C-5 position. If the nucleobase is a cytosine or a derivative thereof, the group L can preferably be bound to the N-4 position. If the nucleobase is a purine base (A, G or a derivative thereof), the Group L should preferably be attached to the C-8 position. If the nucleobase is adenine or a derivative thereof, the group L can preferably be bound to the N-6 position.
- the group L can preferably be bound to the N-2 position. If the nucleobase is a 7-deazapurine, the group L can preferably be bound to the C-7 position.
- the nucleobase is particularly preferably a pyrimidine base and the group L is bound to the C-5 position.
- Group L is a group preferably selected from signaling groups, intercalators and pharmaceutically active groups or a group capable of coupling to one of the aforementioned groups.
- Group L can carry one or more protecting groups if necessary to prevent undesired reactions under the conditions prevailing during PNA synthesis.
- the group L is preferably coupled to the nucleobase B via a bond which is stable under conditions in which the intermediate protective groups used for the particular synthesis strategy are split off.
- L is preferably not an exocyclic amino function directly protected by a base-labile protective group.
- an exocyclic amino function is understood to mean an amino function located directly (i.e. not via a linker) on the heterocycle.
- Group L is preferably a signaling group or a reporter molecule. All previously known signaling groups for polypeptides and nucleotides, in particular non-radioactive signaling groups, are suitable for this. Examples of such groups are chromogens (fluorescent or luminescent groups, dyes), enzymes, NMR-active groups or metal particles, haptens, e.g. As digoxigenin, or biotin and derivatives thereof, which are bindable with streptavidin or avidin. Furthermore, the marking group can also have a pho- to be activatable cross-linking group, e.g. B. an azido or aziring group.
- Particularly preferred signal-generating groups are metal chelates detectable by electrochemiluminescence, particularly preferably ruthenium chelates, e.g. B. a ruthenium (bispyridyl) 3 2+ chelate.
- ruthenium labeling groups are described, for example, in EP-A-0580 979, WO 90/053 01, WO 90/11 511 and WO 92/14 138. These documents are .. 'up due to the reference into the present description.
- the group L can also be an intercalator, which can be incorporated into a PNA-nucleic acid hybrid and, if necessary, in this way enables its detection.
- Suitable intercalators are e.g. B. thiazole orange, ethidium bromide 15 or propidium iodide.
- the group L can be a pharmaceutically active group, e.g. B. an RNA-cleaving group, such as an imidazole-containing radical (cf. WO 93/17 7117, DE-A-44 25 20 311, WO 96/07 667) or a group which has the pharmacodynamic or pharmacokinetic properties can improve (WO94 / 068 15).
- an RNA-cleaving group such as an imidazole-containing radical (cf. WO 93/17 7117, DE-A-44 25 20 311, WO 96/07 667) or a group which has the pharmacodynamic or pharmacokinetic properties can improve (WO94 / 068 15).
- marker groups can be introduced into the monomer unit before the synthesis of the nucleic acid-binding oligomers, provided that they are compatible with the conditions prevailing in the particular synthesis strategy. Compatibility can
- oligomer 30 can be achieved or / and improved by inserting appropriate groups on functional protective groups such as amino or OH groups of the labeling groups.
- functional protective groups such as amino or OH groups of the labeling groups.
- suitable groups that are stable during oligomer synthesis are luminescent metal chelates such as ruthenium
- the group L can also be a residue which is capable of coupling to a labeling group.
- suitable residues are reactive groups such as amino groups or active esters, which are preferably connected to the nucleobase or the peptide backbone via suitable linkers.
- L in this case preferably has the structure -R '-NHY, where R' is a C 2 -C 10 alkylene, alkenylene or alkynylene radical which optionally contains heteroatoms and Y is a protective group.
- nucleic acid-binding peptide oligomers are compounds composed of several monomeric building blocks, the linkage of the building blocks being at least partly via peptide bonds or other acid amide bonds (e.g. CONH, CONR 2 , CSNH, CSNR 2 , SONH, SONR 2 , S0 2 NH or S0 2 NR 2 , where R 2 is as previously defined).
- These oligomers can also bind to nucleic acids via base pairing. Such a base pairing usually takes place through hydrogen bonds between complementary nucleobases.
- Nucleic acid-binding oligomers can basically bind to nucleic acids in two ways. In the first case, a strand of the nucleic acid-binding oligomer binds to a selected region of a single-stranded nucleic acid, a double strand or duplex being formed. In the second case, two molecules of the nucleic acid-binding oligomer can form a complex with the selected region of a nucleic acid, a triple helix strand or a triplex being formed. Nucleic acid-binding oligomers are, for example, peptidic nucleic acids, as are known from WO92 / 20 702.
- the present invention not only covers PNA with identical, repeating backbone groups, but also nucleic acid-binding oligomers in which the backbone consists of different monomeric subunits, and as described in WO 95/14 706.
- Compounds are also covered according to EP-A-0 627 677, where mixed structures of peptide-bound monomers and oligonucleotide subunits are disclosed.
- compounds are detected as disclosed in 'WO 96/20 212 and EP-A-0 700 928. The aforementioned documents become part of the description by reference.
- nucleic acid-binding oligomers are peptidic nucleic acids according to formula (III):
- n is an integer of at least 3
- x is an integer of 2 to n-1
- each of the groups B 1 to B n is a nucleobase as previously defined
- each of the groups C 1 -C n has the meaning (CR 6 R 7 ) y , preferably CR 6 R 7 , CHR 6 CHR 7 or CR 6 R 7 CH 2 , where R 6 is hydrogen and R 7 is selected from the group consisting of the side chains of naturally occurring alpha-amino acids or R 6 and R 7 are selected independently from the group consisting of hydrogen, Ci-Cg-alkyl, aryl, aralkyl, heteroaryl, hydroxy, CVCg-alkoxy, Alkylthio, NR 3 R 4 and SR 5 , where R 3 and R 4 are as defined below and R 5 is hydrogen, or with hydroxy, Alkoxy or Is alkyl, or R 6 and R 7 together are an alicyclic or form a heterocyclic system or is C ⁇ C "CO, CS or CNR 3 ;
- each of the radicals D ⁇ D has the meaning (CR 6 R 7 ) Z , preferably CR 6 R 7 , CHR 6 CHR 7 or CH 2 CR 6 CR 7 ', where R 6 and R 7 are as previously defined, y and z are integers from 0 to 10, the sum of y + z being at least 2, preferably more than 2 but not more than 10;
- each of the radicals G ⁇ G " " 1 has the meaning -NR 3 CO-, -NR 3 CS-, -NR 3 SO- or -NR 3 S0 2 in any orientation, where R 3 is as defined below;
- a 1 -A n is a group of the formula (purple), (Illb), (IIIc) or (Illd) and E ⁇ E "N or R 3 N + or
- X is 0, S, Se, NR 3 , CH 2 or C (CH 3 ) 2 ,
- Y is a single bond, O, S or NR 4 ,
- p and q are each an integer from 0 to 5, the sum p + q preferably not being greater than 5;
- r and s are each integers from 0 to 5, the sum r + s preferably not being greater than 5;
- each of the radicals R 8 and R 9 is independently selected from the group consisting of hydrogen, hydroxy, amine, halogen, C 1 -C 4 alkoxy, Alkythio and optionally substituted C ⁇ -C 4 alkyl, the substituents preferably consisting of hydroxy, C-. - C 4 alkoxy or C 1 -C 4 alkylthio groups can be selected;
- each of R 3 and R 4 is independently selected from the group consisting of hydrogen, C-. - ⁇ alkyl, which is optionally substituted with hydroxy or C x -C 4 alkoxy or C ] , -C 4 alkylthio, hydroxy, Ci-Cg alkoxy, Alkythio and amine;
- Q 'and I' are independently selected from the group consisting of NH 2 , CONH 2 , COOH, hydrogen, -Alkyl, an amine blocked by a protective group, marking groups, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, nucleosides, nucleotides, nucleoside diphosphates, nucleoside triphosphates, oligonucleotides including oligoribonucleotides and oligodeoxyribonucleosides, and oligodeoxyribonucleotides insoluble polymers and nucleic acid binding groups and
- nucleic acid binding oligomers comprise at least one monomeric subunit of the general formula (IV):
- B is a nucleobase as previously defined
- k, 1 and m are independently an integer from 0 to 5
- R 7 is selected from the group consisting of hydrogen and the side chains of naturally occurring alpha-amino acids.
- PNA building blocks The synthesis of PNA building blocks according to the invention is described using the example of the nucleobase thymidine, into which an allylamino group has been introduced, which is used for coupling to other groups, e.g. B. marker groups such as Ru (bipyrid-yl) 3 f is.
- uracil-1-methyl acetate (2) was prepared starting from uracil (1) and methyl bromoacetate, which was then saponified to the corresponding sodium salt (3) with sodium hydroxide solution.
- the desired amino-modified thymine PNA building block (11) was obtained by ester.
- the Z-protected D-Lys-Thy ⁇ nin building block 12 which bears a group capable of coupling on the peptide backbone (FIG. 3), is a known compound which has hitherto been used to produce PNA sequences with improved solubility.
- the PNA synthesis was carried out according to the method described in T. Koch et al. , Automated PNA Synthesis, Int. J. Peptide Protein Res., In press, presented on an ABI433A peptide synthesizer.
- the nucleic acid-binding oligomers according to the invention can of course be synthesized in various ways.
- a Boc / Z protecting group strategy is used in the examples of the present application, i. H. the intermediate protecting group of the PNA monomer building blocks is Boc (cleavage with trifluoroacetic acid), the nucleobases are protected with Z (benzyloxycarbonyl; cleavage with trifluoromethanesulfonic acid / trifluoroacetic acid mixture).
- the amino groups present on the modified monomers according to the invention can also be protected with Z in this synthesis strategy.
- base-labile intermediate amino protecting groups are used for PNA synthesis, especially Fmoc.
- the nucleobases are with protected against base compatible protective groups, e.g. B. Monomethoxytrityl, Boc etc.
- the additional amino group introduced by the modification according to the invention and to be permanently protected during the synthesis can also be protected here with monomethoxytrithyl or Boc.
- nucleic 'ynoic Acid binding peptidic oligomer which contains at least one monomeric building block of the pelt gekop- a marker group to a nucleobase and / or contains to the peptide backbone.
- the nucleic acid-binding oligomer preferably contains at least one monomeric building block selected from compounds of the formula (I) and (II).
- the oligomer according to the invention when hybridized with a complementary nucleic acid (1), the resulting hybrid, which can be a double strand or a triple strand, has a higher melting point than a hybrid which contains an oligomer with the same sequence but without a labeling group, or (2) weaker destabilization takes place in a PNA-nucleic acid hybrid than in a nucleic acid-nucleic acid hybrid.
- the oligomer according to the invention can contain several identical or different marker groups and, in addition, can also be coupled to other identical or different marker groups at the N- and C-terminus.
- the oligomer according to the invention is particularly preferably a peptide nucleic acid and has a structure of the general formula
- the PNA preferably contains at least one monomeric building block of the general formula
- the nucleic acid-binding oligomers according to the invention are used for hybridization to nucleic acids.
- methods for the detection and / or isolation of nucleic acids come into consideration, for. B. Diagnostic detection methods.
- the oligomers according to the invention, especially when L is a pharmaceutically active group, also in therapeutic processes, e.g. B. can be used as antisense molecules.
- the invention also relates to reagents and reagent kits for hybridization with nucleic acids which, in addition to other test components, contain a nucleic acid-binding oligomer according to the invention.
- SEQ ID NO. 1 the nucleotide sequence of a Chla ydien probe
- SEQ ID NO. 2 the nucleotide sequence of a reference or counter-strand probe to that in SEQ ID NO. 1 sequence shown
- FIG. 1 the schematic representation of synthesis strategies with which the production of monomer building blocks according to the invention is not successful
- FIG. 2 shows the schematic representation of a synthesis strategy with which the monomer building blocks according to the invention (for example 11) can be produced
- FIG. 3 shows the structure of a PNA monomer (12) which is suitable for introducing marker groups on the peptide backbone
- FIG 4 the structures of PNA monomers, linkers, labeling groups and a synthetic support resin.
- Lithium hydroxide stirred overnight at room temperature.
- MBHA resin (Novabiochem; 0.56 mmol / g) is left to swell in dichloromethane overnight. It is then filtered off and washed with 5% diisopropylethylamine solution in N-methylpyrrolidone (NMP). Then 0.77 ml of 0.26 M N t are added.
- the PNA synthesis takes place on an ABI 433A peptide synthesizer from Applied-Biosystems with modified software.
- the syntheses are carried out in 5 ⁇ mol amounts in a 3 ml reaction vessel.
- a smaller measuring loop 150 ⁇ l is used.
- the monomer blocks are dissolved in NMP and injected into individual cartridges (140 ⁇ l, 0.26 M).
- the MBHA carrier material derivatized with Boc-Gly is filled into the 3 ml reaction vessel and attached to the synthesizer.
- Trifluoroacetic acid / m cresol 95: 5 (2 x 180 sec); Bottle position 2) is used to split off the Boc protecting group.
- the coupling time is 10 min, the monomer concentration during the coupling is 0.08 M.
- a capping module with acetic anhydride / NMP / pyridine 1:25:25 (1 min; bottle position 4).
- Each synthesis cycle is completed with an NMP wash module.
- a dichloromethane wash module follows to dry the resin.
- the couplings of the modified building blocks in particular are checked by a qualitative Kaiser test.
- the PNA is separated from the resin and the protective groups in a manual step outside the device in a closable glass frit.
- the resin is first washed with trifluoroacetic acid (TFA), then shaken for 1.5 hours
- the analysis of the purified PNAs is carried out mass spectrometrically with MALDITOF-MS. 0
- the PNA 20 is produced according to the synthesis method described above (Example 8), using component 11 as the 0 coupling component at position 12.
- the terminal Boc protective group is split off with TFA / m-cresol 95: 5 (180 sec).
- the resin is then washed with successive NMP and dichloromethane washes.
- the terminal amino function is then acetylated with acetic acid / anhydride / pyridine / NMP 1: 2: 2 (1 hour).
- the capping solution is then suctioned off and washed with NMP and dichloromethane. Cleavage and HPLC purification are carried out as described above (Example 8).
- MALIDOTF-MS 5545.9 ( ⁇ 0.005%).
- a 43 OD 260 aliquot of the purified PNA is evaporated to dryness.
- the PNA is then dissolved in 0.1 M NaHC0 3 buffer pH 8.5 (1 ml).
- the pH is checked and, if necessary, readjusted, then 2 mg of N-hydroxysuccinimide ester of Ru 5 (bipyridyl) 3 acid (Boehringer Mannheim, Ident No. 171 74 64) are dissolved in 1 ml of DMSO and shaken overnight to give the released amino function of the incorporated building block 11 to mark. It is then dialyzed against water (1000 MWCO, SpectraPor 6).
- building block 12 The synthesis of building block 12 is carried out as in G. Haaima et al. , Appl. Chem., 1996, 108, 2068-2070.
- the PNA 21 is produced according to the synthetic method described above (Example 8) using the building block 12 as the twelfth coupling building block (5 ⁇ mol scale). Yield: 114 OD 260 MS (MALDITOF): 6228.0 ( ⁇ 0.02%)
- the sequence is derived from a chlamydial probe (with the basic nucleotide sequence given in SEQ ID NO. 1 as shown in FIG. 15):
- Ru-U is the built-in building block 11, which was post-labeled with Ru (bpy) 3 -OSu on the amino function at C-5 by Uracil.
- T Lys-Ru is the built-in building block 12, which has been post-labeled with Ru (bpy) 3 -OSu on the amino function of the lysine in the backbone.
- Ru-Lys, Ru, Bio and Ado have the meaning shown in Fig. 4.
- oligonucleotides (with the basic nucleotide sequence given in SEQ ID NO.2 as shown in FIG. 13 or SEQ ID NO 1 as shown in FIG. 14) are synthesized as reference or counter strand according to the standard phosphoramidite method:
- Ru-U is the built-in DNA analogue to building block 11, which was post-labeled with Ru (bpy) 3 -OSu on the amino function at C-5 of the uracil.
- the 5 'terminal Ru and Bio are each coupled via the corresponding phosphoramidite derivative.
- the melting temperatures of hybrids of two complementary oligomers are determined on a Uvikon 931 spectral photometer from Kontron.
- the temperature of the cuvette blocks is controlled by a Haake DC5 heating / cooling thermostat,
- the internal T m control is carried out in a cuvette using a PDIO thermal sensor.
- a contra software is used. It is measured in steps of 0.5 ° C. in 100 mM NaCl, 10 mM Na phosphate, 0.1 mM EDTA, pH 7 as a melting curve buffer. Both oligomers are used in equimolar amounts.
- the final oligomer concentration is 2.5 nmol / ml.
- Tm experiments are carried out.
- the Tm values are summarized in Tab. 1.
- the Tm of the DNA-DNA duplex is 56 ° C. While 5 'biotinylation leaves the Tm practically unaffected (55.9 ° C), 5' ruthenylation leads to a slightly increased Tm of 56.7 ° C by 0.7 ° C. The same picture is shown in the DNA-PNA duplex.
- the unlabeled PNA-DNA duplex has a Tm of 73.5 ° C, amino-terminal biotinylation of the PNA does not affect stability (73.5 ° C), amino-terminal ruthenylation also leads to an increase in stability of 0.7 ° C to 74.2 ° C.
- Ru labeling on an internal Lys amino function provides the same gain in stability from 0.7 ° C to 74.2 ° C as amino terminal Ru installation.
- Internal Ru labeling at the C-5 position of the uracil (component 11) even leads to the highest stabilization from 1.5 ° C to 75.0 ° C. It was also surprising to find that internal Ru labeling at the C-5 base position of the uracil in DNA-DNA duplexes leads to a slight de-stabilization of the double strand, while analogous internal labeling of the PNA leads to a stabilization of the PNA-DNA - duplexes leads.
- MOLECULE TYPE Other nucleic acid
- SEQUENCE DESCRIPTION SEQ ID NO: 1:
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU72096/98A AU7209698A (en) | 1997-03-25 | 1998-03-24 | Novel monomer elements for marking peptidic nucleic acids |
EP98919138A EP0970113A1 (de) | 1997-03-25 | 1998-03-24 | Neue monomerbausteine zur markierung von peptidischen nukleinsäuren |
US09/381,301 US6388061B1 (en) | 1997-03-25 | 1998-03-24 | Monomeric building blocks for labeling peptide nucleic acids |
JP54324298A JP2002503265A (ja) | 1997-03-25 | 1998-03-24 | ペプチド核酸を標識するための新規モノマー構成体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19712530.1 | 1997-03-25 | ||
DE19712530A DE19712530A1 (de) | 1997-03-25 | 1997-03-25 | Neue Monomerbausteine zur Markierung von peptidischen Nukleinsäuren |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998042735A1 true WO1998042735A1 (de) | 1998-10-01 |
Family
ID=7824578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/001723 WO1998042735A1 (de) | 1997-03-25 | 1998-03-24 | Neue monomerbausteine zur markierung von peptidischen nukleinsäuren |
Country Status (6)
Country | Link |
---|---|
US (1) | US6388061B1 (de) |
EP (1) | EP0970113A1 (de) |
JP (1) | JP2002503265A (de) |
AU (1) | AU7209698A (de) |
DE (1) | DE19712530A1 (de) |
WO (1) | WO1998042735A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19909373A1 (de) * | 1999-03-03 | 2000-10-05 | Ugichem | Neue PNA-Monomere, daraus resultierende PNA-Oligomere und deren Verwendung |
EP2286792A1 (de) | 1999-02-26 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Mikroemulsionen mit einer adsorbierenden Oberfläche, enthaltend eine Mikrotropfenemulsion |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6331618B1 (en) * | 1999-05-13 | 2001-12-18 | Pe Corporation (Ny) | Compositions of solvents and high concentrations of nucleic acid analogs |
US7648678B2 (en) | 2002-12-20 | 2010-01-19 | Dako Denmark A/S | Method and system for pretreatment of tissue slides |
IL160492A0 (en) * | 2004-02-19 | 2004-07-25 | Univ Ben Gurion | Photoreactive compound specifically binding to calcium binding proteins |
KR20170007181A (ko) | 2015-07-10 | 2017-01-18 | 3스캔 인크. | 조직학적 염색제의 공간 다중화 |
WO2017049213A1 (en) | 2015-09-16 | 2017-03-23 | PetaOmics, Inc. | Methods and compositions for genomic target enrichment and selective dna sequencing |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2284208A (en) * | 1993-11-25 | 1995-05-31 | Pna Diagnostics As | Nucleic acid analogues with a chelating functionality for metal ions |
WO1995016202A1 (en) * | 1993-12-06 | 1995-06-15 | Pna Diagnostics A/S | Labelling of nucleic acid analogue-peptide chimerae |
DE4408533A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | PNA-Synthese unter Verwendung einer basenlabilen Amino-Schutzgruppe |
WO1996011205A1 (en) * | 1994-10-06 | 1996-04-18 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid conjugates |
EP0781853A2 (de) * | 1995-12-12 | 1997-07-02 | Eli Lilly And Company | Verfahren zur Messung von Nukleinsäuren |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071699A (en) * | 1996-06-07 | 2000-06-06 | California Institute Of Technology | Nucleic acid mediated electron transfer |
-
1997
- 1997-03-25 DE DE19712530A patent/DE19712530A1/de not_active Withdrawn
-
1998
- 1998-03-24 EP EP98919138A patent/EP0970113A1/de not_active Withdrawn
- 1998-03-24 AU AU72096/98A patent/AU7209698A/en not_active Abandoned
- 1998-03-24 JP JP54324298A patent/JP2002503265A/ja not_active Ceased
- 1998-03-24 US US09/381,301 patent/US6388061B1/en not_active Expired - Lifetime
- 1998-03-24 WO PCT/EP1998/001723 patent/WO1998042735A1/de not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2284208A (en) * | 1993-11-25 | 1995-05-31 | Pna Diagnostics As | Nucleic acid analogues with a chelating functionality for metal ions |
WO1995016202A1 (en) * | 1993-12-06 | 1995-06-15 | Pna Diagnostics A/S | Labelling of nucleic acid analogue-peptide chimerae |
DE4408533A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | PNA-Synthese unter Verwendung einer basenlabilen Amino-Schutzgruppe |
WO1996011205A1 (en) * | 1994-10-06 | 1996-04-18 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid conjugates |
EP0781853A2 (de) * | 1995-12-12 | 1997-07-02 | Eli Lilly And Company | Verfahren zur Messung von Nukleinsäuren |
Non-Patent Citations (1)
Title |
---|
HAAIMA, GERALD ET AL: "Peptide nucleic acids (PNAs) containing thymine monomers derived from chiral amino acids: hybridization and solubility properties of D-lysine PNA", ANGEW. CHEM., INT. ED. ENGL. (1996), 35(17), 1939-1941 CODEN: ACIEAY;ISSN: 0570-0833, 20 September 1996 (1996-09-20), XP002075301 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2286792A1 (de) | 1999-02-26 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Mikroemulsionen mit einer adsorbierenden Oberfläche, enthaltend eine Mikrotropfenemulsion |
DE19909373A1 (de) * | 1999-03-03 | 2000-10-05 | Ugichem | Neue PNA-Monomere, daraus resultierende PNA-Oligomere und deren Verwendung |
US7105648B1 (en) | 1999-03-03 | 2006-09-12 | Ugichem Gmbh | Oligomers substituted by phosphite acid ester, phosphonic acid or carbaborane functions and the corresponding PNA monomers |
Also Published As
Publication number | Publication date |
---|---|
JP2002503265A (ja) | 2002-01-29 |
EP0970113A1 (de) | 2000-01-12 |
AU7209698A (en) | 1998-10-20 |
US6388061B1 (en) | 2002-05-14 |
DE19712530A1 (de) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0739898B1 (de) | Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE69637389T2 (de) | Covalent gekoppelte oligonukleotid (minor-groove-binder)-konjugate | |
EP0399330B1 (de) | Modifiziertes Phosphoramidit-Verfahren zur Herstellung von modifizierten Nukleinsäuren | |
EP0688784B1 (de) | 3'-Modifizierte Oligonucleotid-Derivate | |
US7897346B2 (en) | Polyamide nucleic acid derivatives and agents, and processes for preparing them | |
DE4408528A1 (de) | Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung | |
DE69725440T2 (de) | 2-substituierte nukleosid- und oligonukleotid- derivate | |
EP0646596A1 (de) | Nukleinsäure-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik | |
EP1831246B1 (de) | Sonde zum nachweis von nukleinsäuren | |
WO1998042735A1 (de) | Neue monomerbausteine zur markierung von peptidischen nukleinsäuren | |
EP1282639B1 (de) | Peptidnukleinsaure-derivate mit negativer ladung, mittel und verfahren zu ihrer herstellung | |
DE60225652T2 (de) | Oligonukleotidmarkierungsreagenzien auf der Basis von azyklischen Nukleosiden, und deren derivatisierte Konjugate | |
DE19508923A1 (de) | Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung | |
EP0996631A1 (de) | Modifizierte nukleinsäureanaloga | |
DE10139730A1 (de) | Verfahren zur Herstellung CNA | |
DE4420737A1 (de) | Neue 3'-Modifizierte Oligonucleotid-Derivate | |
DE4015735A1 (de) | Nukleoside als synthone fuer die rna-synthese | |
DE19543865A1 (de) | Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE4424263A1 (de) | Neue 3'-Modifizierte Oligonucleotid-Derivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN IL JP KR NO NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998919138 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 543242 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998919138 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09381301 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20000407A Country of ref document: HR |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998919138 Country of ref document: EP |